Y&R Network Is Recognized With 98 Lions Across 26 Countries And 20 Categories

Logo

Y&R Network Is Recognized With 98 Lions Across 26 Countries And 20 Categories

Agency Remains Among Top 5 Global Networks; Y&R Wins Its First Glass Lion; VML More Than Doubles Its Lions

PR Newswire

NEW YORK, June 24, 2017 /PRNewswire/ – Y&R announced today it has been awarded a total of 98 Lions at this year’s Cannes Lions Festival of Creativity. This includes the agency’s first Glass Lion and a Grand Prix in Mobile

Y&R logo

Y&R’s wins included its first Glass Lion, 1 Grand Prix, 12 Gold, 30 Silver and 55 Bronze. The agency was also Shortlisted 195 times.

Key highlights for Y&R and VML this year include:

  • The global network won in 36 offices, 26 countries and across 20 categories.
  • Several firsts for the network: DY&R Tokyo was awarded the first Glass Lion for Tokyo and for Y&R, for Recruit Lifestyle Seem “The Family Way.” The campaign also won a Grand Prix, Gold and Silver. VML won the network’s first Entertainment Lion for Absolut Vodka “One Source.” Advantage Y&R in Namibia brought home the country’s first shortlist for Greenpeace “Trash Masks.”
  • Y&R Madrid was the most awarded agency in its market.
  • Y&R and VML were awarded 14 Lions in Africa, and won more Mobile Lions than any other agency on the continent.
  • Y&R New Zealand’s “McWhopper,” one of last year’s most awarded campaigns, returned to Cannes this year to earn a Gold Creative Effectiveness Lion.
  • VML won 17 Lions in North America, including Wendy’s viral “#NuggsforCarter” and “Twitter Beef.”
  • Y&R Dubai and Y&R’s New Moments in Belgrade collaborated on “One Book,” for the Interreligious Council in Bosnia and Herzogovina. Researched by Christian and Muslim theologians, the campaign brings together similar passages from the Bible and the Quran to show that our common beliefs unify us more than our differences. It won an extraordinary five Lions, including a Gold for Design.

“We are very pleased that, for the fifth year in a row, we have had a strong performance at Cannes, multiple firsts including a Glass Lion, another Grand Prix and great work created for so many major brands both global and local. This year, almost every one of our offices submitted work to Cannes — which we think is not simply a testament to the great creativity that is flourishing in all our offices around the world, but also a reflection of the great support we have from clients to courageously create work that continues to meet the standard our founder set to Resist the Usual,” said Tony Granger, Y&R Global Chief Creative Officer.

David Sable, Global CEO of Y&R said, “I am once again proud of our network and thrilled to see that 26 countries contributed to our standing among the top global networks. Y&R has long believed that a global network’s strength comes from its deep roots in its markets matched by a vision and mission that is shared globally and supported by the common tools, resources and technology around the world. It is this dual-pronged strategy that helps us deliver work that is not only recognized for its creativity but also for its effectiveness. Strong performances at Cannes and Effies in 2017 give our clients the best of both worlds.”

About Y&R
Y&R is one of the leading and most iconic global marketing communications companies. We operate as a Global Boutique, connecting deep insights from local business needs and consumers with strategies and objectives that travel across borders. Y&R Inspire Change is the agency’s global social impact practice geared towards both nonprofit organizations and brands incorporating social purpose strategies. United by a global infrastructure and common tools and technology, all our clients have access to people and resources from everywhere in our network.

Y&R has 189 offices in 93 countries around the world, with clients that include Bel Brands, Campbell’s Soup Company, Colgate-Palmolive, Danone, Dell, Telefonica and Xerox, among many others. Y&R is part of WPP (NASDAQ: WPPGY).

Follow us on Twitter and Instagram

Contact:
Aviva Ebstein
Aviva.ebstein@yr.com 
+1 917-679-8691

or

Jodi Lefkowitz
Jodi.lefkowitz@yr.com
+1 212-210-4651

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/yr-network-is-recognized-with-98-lions-across-26-countries-and-20-categories-300479266.html

SOURCE Y&R

European Hematology Association: Early Metabolic Response Determination by FDG-PET Allows Substantial Reduction of Chemotherapy and its Toxicity in Patients with Advanced Stage Hodgkin Lymphoma: the GHSG HD18 Study

Logo

European Hematology Association: Early Metabolic Response Determination by FDG-PET Allows Substantial Reduction of Chemotherapy and its Toxicity in Patients with Advanced Stage Hodgkin Lymphoma: the GHSG HD18 Study

PR Newswire

MADRID, June 24, 2017 /PRNewswire/ —

Hodgkin lymphoma is the most common malignancy of young adults. Intensive chemotherapy with eight or six cycles of eBEACOPP is very effective in patients with advanced-stage Hodgkin’s lymphoma (HL), albeit at the expense of severe toxicities. Aiming at better tolerability, we investigated whether metabolic response determined by positron emission tomography after two cycles (PET-2) would allow us to select patients, who could be treated with reduced intensity (four cycles) without loss of efficacy.

     (Logo: http://mma.prnewswire.com/media/524821/EHA_Logo.jpg )

The GHSG HD18 trial was conducted in five European countries (Germany, Switzerland (SAKK), Austria (AGMT), Czech Republic, the Netherlands). Between 05/2008 and 07/2014, 2101 patients aged 18-60 years with newly diagnosed, advanced-stage HL were recruited, of whom 1005 were PET-2 negative.

Reduced therapy with four cycles of eBEACOPP was non-inferior to 6/8 cycles in terms of five-year progression-free survival (92·2% versus 90·8%, difference +1·4%, 95% CI -2·7-5·4). We observed no treatment related mortality in the experimental group, fewer infections, less organ toxicities and a very low incidence of second acute myeloid leukemia. Overall, this resulted in a significantly superior five-year overall survival (97·7% versus 95·4%, log-rank p=0·004) for the patient cohort with reduced treatment.

In conclusion, treatment with four cycles of eBEACOPP in patients with negative PET-2 is extremely effective, very safe, short (12 weeks), and affordable. Results for efficacy and safety compare favorably with any other published treatment strategy.

We therefore recommend PET-2-guided eBEACOPP for patients with advanced-stage HL.

Presenter:  Dr Peter Borchmann

Affiliation:  Uniklinik Koeln, Cologne, Germany

Topic:  TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP

Abstract S150 will be presented by Peter Borchmann on Friday, June 23 15:45 – 17:00 in Hall A.

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma – diagnosis and treatment; red blood cells, white blood cells- and platelet disorders; thrombosis and bleeding disorders.

SOURCE European Hematology Association

European Hematology Association: Global Trial of the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma: An Interim Analysis of the JULIET Study

Logo

European Hematology Association: Global Trial of the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma: An Interim Analysis of the JULIET Study

PR Newswire

MADRID, June 24, 2017 /PRNewswire/ —

CTL019 consists of genetically engineered autologous T cells expressing a chimeric antigen receptor (CAR). Results from a prior single-center phase 2 study at the University of Pennsylvania showed that a single infusion of CTL019 could produce durable remissions in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The JULIET trial is a Novartis-sponsored, single-arm, open-label, multicenter, global phase 2 trial of CTL019 in adult patients with r/r DLBCL. Patients in the JULIET trial had relapse or progression after at least two prior lines of therapy and were not candidates for stem cell transplant. Cryopreserved leukapheresis products were used to manufacture CAR T cells, which were provided to patients at 27 centers in 10 countries on four continents. The primary endpoint was centrally reviewed best overall response rate (ORR: complete response [CR] + partial response [PR]). 85 patients received a single dose of CTL019. Among 51 patients with ≥3 months follow-up or earlier discontinuation, best ORR was 59% (43% achieved CR and 16% achieved PR). The JULIET trial met its primary endpoint. All patients in CR at three months remained in CR at data cutoff. All-grade and grade 3 or 4 cytokine release syndrome (CRS) occurred in 57% and 26% of treated patients, respectively; no CRS-related deaths were reported. 21% and 13% of patients had all-grade and grade 3 or 4 neurologic events, respectively; no cases of cerebral edema were reported. No deaths were attributed to CTL019. This preplanned interim analysis of a global study of CTL019 in adults with r/r DLBCL is consistent with the high response rates and durable responses observed in the previous single-center experience.

     (Logo: http://mma.prnewswire.com/media/524821/EHA_Logo.jpg )

Presenter:  Dr Giles Salles

Affiliation:  Hospices Civils de Lyon, Université de Lyon, Lyon, France

Topic:  GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS

Abstract LB2604 will be presented by Giles Salles on Saturday, June 24, 11:15 – 12:45 in HALL A.

About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma – diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.

SOURCE European Hematology Association